Melphalan

Generic Name
Melphalan
Brand Names
Alkeran, Evomela, Phelinun, Pepaxti
Drug Type
Small Molecule
Chemical Formula
C13H18Cl2N2O2
CAS Number
148-82-3
Unique Ingredient Identifier
Q41OR9510P
Background

Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard. Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-conditioning before hematopoietic stem cell transplant. It is...

Indication

Melphalan is indicated for use as a high-dose conditioning treatment prior to hematopoietic stem cell transplantation in patients with multiple myeloma. It is also indicated for the palliative treatment of multiple myeloma and for the palliation of non-resectable epithelial carcinoma of the ovary.
...

Associated Conditions
Multiple Myeloma (MM), Unresectable Liver Metastasis, Unresectable Ovarian Cancer (Epithelial)
Associated Therapies
Conditioning regimens for allogeneic stem cell transplantation therapy
Clinical Trials
Related News

Phase I/II Study of Escalating-Dose Melphalan w/Autologous SCS & Amifostine Cytoprotect

First Posted Date
2004-02-20
Last Posted Date
2013-04-26
Lead Sponsor
University of Kentucky
Target Recruit Count
25
Registration Number
NCT00003425
Locations
🇺🇸

Albert B. Chandler Medical Center, University of Kentucky, Lexington, Kentucky, United States

🇺🇸

Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States

🇺🇸

Kimmel Cancer Center of Thomas Jefferson University - Philadelphia, Philadelphia, Pennsylvania, United States

and more 1 locations

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Central Nervous System Lymphoma

Phase 2
Completed
Conditions
Lymphoma
First Posted Date
2004-02-16
Last Posted Date
2013-01-16
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
30
Registration Number
NCT00003632
Locations
🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Rituximab & Combination Chemotherapy Followed by Transplantation in Relapsed or Refractory Non-Hodgkin's Lymphoma

First Posted Date
2004-02-12
Last Posted Date
2023-09-01
Lead Sponsor
University of Nebraska
Target Recruit Count
44
Registration Number
NCT00007852
Locations
🇺🇸

University of Nebraska Medical Center, Omaha, Nebraska, United States

Repeated Bone Marrow Transplantation in Treating Women With Advanced Breast Cancer

Phase 1
Terminated
Conditions
Breast Cancer
First Posted Date
2004-02-09
Last Posted Date
2020-07-14
Lead Sponsor
Louisiana State University Health Sciences Center Shreveport
Target Recruit Count
12
Registration Number
NCT00003086
Locations
🇺🇸

Louisiana State University School of Medicine, Shreveport, Louisiana, United States

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

First Posted Date
2004-02-02
Last Posted Date
2019-11-08
Lead Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Target Recruit Count
131
Registration Number
NCT00005792
Locations
🇺🇸

H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

High Dose Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Intermediate- or High-Grade Non-Hodgkin's Lymphoma

Phase 3
Conditions
Lymphoma
First Posted Date
2004-01-27
Last Posted Date
2013-09-20
Lead Sponsor
Lymphoma Trials Office
Target Recruit Count
500
Registration Number
NCT00003578
Locations
🇨🇿

Charles University Hospital, Prague (Praha), Czech Republic

🇬🇧

City Hospital - Birmingham, Birmingham, England, United Kingdom

🇳🇴

Norwegian Radium Hospital, Oslo, Norway

and more 69 locations

Interferon Alfa Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Multiple Myeloma

First Posted Date
2004-01-22
Last Posted Date
2013-06-26
Lead Sponsor
University of Tennessee
Registration Number
NCT00003007
Locations
🇺🇸

William F. Bowld Hospital, Memphis, Tennessee, United States

🇺🇸

Methodist Healthcare - Hospital of Memphis, Memphis, Tennessee, United States

🇺🇸

Baptist Memorial Hospital, Memphis, Tennessee, United States

and more 1 locations

Tandem Autologous Stem Cell Transplantation in Treating Patients With Primary Systemic (AL) Amyloidosis

First Posted Date
2004-01-12
Last Posted Date
2020-09-17
Lead Sponsor
Boston Medical Center
Target Recruit Count
62
Registration Number
NCT00075621
Locations
🇺🇸

Cancer Research Center at Boston Medical Center, Boston, Massachusetts, United States

2nd Autologous Stem Cell Transplant in Patients With Persistent/Recurrent (AL) Amyloidosis

First Posted Date
2004-01-12
Last Posted Date
2017-01-27
Lead Sponsor
Boston Medical Center
Target Recruit Count
12
Registration Number
NCT00075608
Locations
🇺🇸

Boston University Cancer Research Center, Boston, Massachusetts, United States

N99-01: Combination Chemotherapy, Radiation Therapy, and Stem Cell Transplantation in Treating Patients With Neuroblastoma

Phase 1
Completed
Conditions
Neuroblastoma
First Posted Date
2003-12-23
Last Posted Date
2010-10-15
Lead Sponsor
New Approaches to Neuroblastoma Therapy Consortium
Registration Number
NCT00005978
Locations
🇺🇸

Texas Children's Cancer Center, Houston, Texas, United States

🇺🇸

Children's Hospital Los Angeles, Los Angeles, California, United States

🇺🇸

Children's Memorial Hospital - Chicago, Chicago, Illinois, United States

and more 12 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy